Literature DB >> 6203980

Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.

J R Ortaldo, A T Mason, J P Gerard, L E Henderson, W Farrar, R F Hopkins, R B Herberman, H Rabin.   

Abstract

Highly enriched populations of human large granular lymphocytes (LGL), natural killer (NK) cells, and T cells were obtained from low and high density fractions, respectively, of discontinuous Percoll gradients. The NK cells were composed of 75 to 90% LGL, with the majority of the contaminating cells being monocytes. The T cells were greater than 95% OKT3+. The proliferative and cytotoxic progenitors in both fractions were examined by using a limiting dilution assay with interleukin 2 (IL 2) from four sources: 1) crude supernatant of a gibbon lymphoma (MLA-144), 2) purified (150,000-fold) MLA-144 IL 2, 3) partially purified human IL 2, and 4) purified recombinant human IL 2. The proliferative capacity was measured at day 7 by [3H]thymidine incorporation, whereas the progenitors of cells with NK-like activity were evaluated by assessing cytotoxic activity against K562 cells at day 8 in a 4-hr 51Cr-release assay. The frequency of proliferative progenitors among T cells was approximately 1/5 and was approximately 1/60 with LGL. Titration of the highly purified IL 2 preparation demonstrated that LGL proliferated with as little as 2 U of IL 2. The frequency of detectable cytotoxic progenitors in the LGL population, however, fell sharply when less than 40 U of IL 2 were employed. The T cells failed to demonstrate cytotoxic activity against the NK-susceptible target cells at any concentration of IL 2 tested. The IL 2 preparations also were examined for their ability to directly and rapidly enhance the cytotoxic activity of highly purified NK cells. All four preparations of IL 2 enhanced the cytotoxic activity of LGL without any detectable accessory requirement after incubation for as little as 6 hr, even though the MLA-144 IL 2 preparations were devoid of detectable interferons (IFN). These data indicate that IL 2 has dual effects on NK cells, regulating their activity was well as promoting their proliferation. Collectively, these results demonstrate that highly purified IL 2, devoid of other detectable lymphokines, is capable of supporting the growth of human NK cells and augmenting their in vitro activity. In parallel experiments, these same IL 2 preparations were quite active in causing the proliferation of T lymphocytes, clearly demonstrating a role of IL 2 in promoting the proliferation of NK cells as well as T cells. The mechanism of IL 2 boosting appears to be a direct interaction with LGL, resulting in the production of IFN gamma.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203980

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

Review 1.  Cytokines: past, present, and future.

Authors:  J J Oppenheim
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

2.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

3.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

Authors:  J H Kehrl; M Dukovich; G Whalen; P Katz; A S Fauci; W C Greene
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

4.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Functional surface structures on human natural killer cells.

Authors:  R E Schmidt; T Hercend; S F Schlossman; J Ritz
Journal:  Klin Wochenschr       Date:  1985-12-02

6.  Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2.

Authors:  H P Hughes; M Campos; D L Godson; S Van Drunen Littel-Van den Hurk; L McDougall; N Rapin; T Zamb; L A Babiuk
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

7.  Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis.

Authors:  Y Mizoguchi; T Shin; Y Sakagami; S Seki; T Kuroki; K Kobayashi; S Yamamoto; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1988-04

8.  Characterization of human interleukin 2 derived from Escherichia coli.

Authors:  S M Liang; B Allet; K Rose; M Hirschi; C M Liang; D R Thatcher
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

9.  Purification and characterization of a high-molecular-weight form of recombinant human interleukin-2.

Authors:  Z Ahmad; D Ciolek; Y C Pan; H Michel; F R Khan
Journal:  J Protein Chem       Date:  1994-10

10.  A 100-kilodalton protein is associated with the murine interleukin 2 receptor: biochemical evidence that p100 is distinct from the alpha and beta chains.

Authors:  M Sharon; J R Gnarra; W J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.